港股异动 | 诺诚健华午后拉升涨超15%，ICP-B794近日获批临床，机构称公司未来催化剂丰富
诺诚健华午后涨超15%，截至发稿，涨15.46%，报15.98港元，成交额8.05亿港元。
消息面上，7月3日，诺诚健华宣布其自主研发的靶向B7-H3的新型ADC创新药ICP-B794获得国家药品监督管理局（NMPA）药品审评中心（CDE）批准，可以开展临床研究。目前全球尚无B7-H3靶向疗法获批上市，诺诚健华这一创新成果具有先发优势。
太平洋证券指出，未来12个月内公司催化剂丰富，血液瘤领域，坦昔妥单抗（CD19）用于r/r DLBCL获批上市；ICP-248（BCL2）用于BTKi经治的r/r NHL临床、联合奥布替尼治疗1L CLL/SLL的2期临床的长期疗效数据读出；联合奥布替尼治疗1L CLL/SLL 的3期临床完成入组。自免领域，奥布替尼ITP 3期完成患者入组，SLE 2b期25Q4数据读出，PPMS和SPMS全球3期临床启动并完成首例患者入组；ICP-332（TYK2 JH1）特应性皮炎3期临床、白癜风2期临床完成患者入组；ICP-488（TYK2 JH2）银屑病3期临床完成患者入组。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10